Novel and emerging therapies for B cell lymphoma
Abstract Lymphomas are a heterogeneous group of lymphoproliferative disorders, with unique clinical and biological characteristics that exhibit variable response to therapy. Advances in chemo-immunotherapy have improved outcomes in a number of lymphoma subtypes; however, the prognosis for many patie...
Päätekijät: | Sabarish Ayyappan, Kami Maddocks |
---|---|
Aineistotyyppi: | Artikkeli |
Kieli: | English |
Julkaistu: |
BMC
2019-07-01
|
Sarja: | Journal of Hematology & Oncology |
Aiheet: | |
Linkit: | http://link.springer.com/article/10.1186/s13045-019-0752-3 |
Samankaltaisia teoksia
-
Correction to: Novel and emerging therapies for B cell lymphoma
Tekijä: Sabarish Ayyappan, et al.
Julkaistu: (2021-02-01) -
Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR‐T cell infusion
Tekijä: Paulus A. F. Geerts, et al.
Julkaistu: (2023-06-01) -
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma
Tekijä: Alvaro J. Alencar, et al.
Julkaistu: (2021-11-01) -
Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma
Tekijä: Yifan Pang, et al.
Julkaistu: (2024-04-01) -
Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
Tekijä: Mohty R, et al.
Julkaistu: (2023-04-01)